Efficacy evaluation
Tumors, PD, SD
TUMORS, BRAIN METASTASIS, DISEASE
Imaging examination and hematological examination were carried out for all patients before enrollment and at the end of every 2 cycles of treatment after enrollment. At baseline and after every 2 cycles of treatment, patients underwent computed tomography (CT) scans covering the neck, chest, and abdomen. Enhanced brain magnetic resonance imaging (MRI) was required for brain metastasis. Efficacy evaluations were classified as CR, PR, stable disease (SD), or progressive disease (PD) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).